Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PEDIARIX: clinical trials.

Sylvia H Yeh1

  • 1UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA, 1124 W. Carson St, Liu Research Building, Torrance, CA 90502, USA. syeh@uclacvr.labiomed.org

Expert Review of Vaccines
|May 14, 2005
PubMed
Summary

PEDIARIX is the first pentavalent vaccine in the USA, offering protection against five diseases. This review examines its immunogenicity and safety data in infants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment and Epidemiology of Third-Generation Cephalosporin-Resistant Urinary Tract Infections.

Pediatrics·2022
Same author

Is Acute Solid Food Aversion a Proxy for COVID-19-Related Olfactory and Gustatory Dysfunction?

Pediatrics·2021
Same author

Is Acute Solid Food Aversion a Proxy for COVID-19-Related Olfactory and Gustatory Dysfunction?

Pediatrics·2021
Same author

Profile of the Pediatric Infectious Disease Workforce in 2015.

Journal of the Pediatric Infectious Diseases Society·2018
Same author

Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).

Vaccine·2013
Same author

Cost-benefit analysis of in-hospital influenza vaccination of postpartum women.

Obstetrics and gynecology·2012

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Immunology

Background:

  • PEDIARIX is the first licensed pentavalent combination vaccine for infants in the USA.
  • It provides protection against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus.

Purpose of the Study:

  • To review available data on the immunogenicity of PEDIARIX.
  • To review available data on the safety of PEDIARIX.

Main Methods:

  • Literature review of published and unpublished studies.
  • Analysis of clinical trial data.
  • Safety surveillance data review.

Main Results:

  • PEDIARIX demonstrated robust immunogenicity against all five antigens.
  • The safety profile of PEDIARIX was found to be acceptable.
  • Common adverse events were generally mild and transient.

Conclusions:

  • PEDIARIX is an effective and safe vaccine for infant immunization.
  • The pentavalent combination vaccine simplifies the infant immunization schedule.
  • Continued surveillance is important to monitor long-term safety and effectiveness.

Related Experiment Videos